NuVasive, Inc. (NUVA): Price and Financial Metrics

NuVasive, Inc. (NUVA): $39.75

0.91 (-2.24%)

POWR Rating

Component Grades








NUVA Price/Volume Stats

Current price $39.75 52-week high $49.53
Prev. close $40.66 52-week low $35.17
Day low $39.51 Volume 31,368,500
Day high $41.00 Avg. volume 1,159,125
50-day MA $40.83 Dividend yield N/A
200-day MA $41.23 Market Cap 2.08B

NUVA Stock Price Chart Interactive Chart >

NUVA Stock Summary

  • NUVA's current price/earnings ratio is 73.28, which is higher than 91.98% of US stocks with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, NUVASIVE INC is reporting a growth rate of -450.56%; that's higher than only 3.28% of US stocks.
  • The volatility of NUVASIVE INC's share price is greater than that of only 10.65% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to NUVA, based on their financial statements, market capitalization, and price volatility, are PLPC, HUN, RFIL, IART, and BSQR.
  • Visit NUVA's SEC page to see the company's official filings. To visit the company's web site, go to

NUVA Valuation Summary

  • In comparison to the median Healthcare stock, NUVA's price/earnings ratio is 167.52% higher, now standing at 73.3.
  • NUVA's price/earnings ratio has moved up 96.1 over the prior 235 months.

Below are key valuation metrics over time for NUVA.

Stock Date P/S P/B P/E EV/EBIT
NUVA 2023-08-31 1.7 2.3 73.3 47.7
NUVA 2023-08-30 1.7 2.4 75.0 48.5
NUVA 2023-08-29 1.7 2.4 74.1 48.1
NUVA 2023-08-28 1.7 2.3 73.7 47.9
NUVA 2023-08-25 1.7 2.3 72.2 47.2
NUVA 2023-08-24 1.6 2.2 70.3 46.3

NUVA Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at 70.2%.
  • Its 5 year net income to common stockholders growth rate is now at 14.76%.
  • Its 5 year net cashflow from operations growth rate is now at 70.2%.
Over the past 34 months, NUVA's revenue has gone up $48,767,000.

The table below shows NUVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,201.942 169.118 40.407
2022-09-30 1,198.568 159.751 -20.405
2022-06-30 1,174.124 170.87 -40.067
2022-03-31 1,158.501 157.074 -37.375
2021-12-31 1,138.988 182.174 -64.086
2021-09-30 1,128.72 217.483 -25.658

NUVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NUVA has a Quality Grade of C, ranking ahead of 59.67% of graded US stocks.
  • NUVA's asset turnover comes in at 0.477 -- ranking 99th of 186 Medical Equipment stocks.
  • DYNT, IRMD, and ELMD are the stocks whose asset turnover ratios are most correlated with NUVA.

The table below shows NUVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.477 0.723 0.034
2021-03-31 0.418 0.697 0.001
2020-12-31 0.411 0.694 0.014
2020-09-30 0.454 0.700 0.027
2020-06-30 0.495 0.706 0.028
2020-03-31 0.595 0.731 0.088

NUVA Price Target

For more insight on analysts targets of NUVA, see our NUVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $74.07 Average Broker Recommendation 1.75 (Moderate Buy)

NuVasive, Inc. (NUVA) Company Bio

NuVasive develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company was founded in 1997 and is based in San Diego, California.

NUVA Latest News Stream

Event/Time News Detail
Loading, please wait...

NUVA Latest Social Stream

Loading social stream, please wait...

View Full NUVA Social Stream

Latest NUVA News From Around the Web

Below are the latest news stories about NUVASIVE INC that investors may wish to consider to help them evaluate NUVA as an investment opportunity.

Should You Investigate NuVasive, Inc. (NASDAQ:NUVA) At US$39.75?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it received a lot of attention from a...

Yahoo | September 5, 2023

Globus Medical (GMED) Completes NuVasive Merger Agreement

Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.

Yahoo | September 4, 2023

Why NuVasive (NUVA) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Yahoo | August 31, 2023

NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle.

Yahoo | August 30, 2023

Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600

S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1:

Yahoo | August 28, 2023

Read More 'NUVA' Stories Here

NUVA Price Returns

1-mo N/A
3-mo N/A
6-mo 0.73%
1-year -4.77%
3-year -14.97%
5-year -29.17%
YTD -3.61%
2022 -21.42%
2021 -6.83%
2020 -27.17%
2019 56.05%
2018 -15.27%

Continue Researching NUVA

Here are a few links from around the web to help you further your research on Nuvasive Inc's stock as an investment opportunity:

Nuvasive Inc (NUVA) Stock Price | Nasdaq
Nuvasive Inc (NUVA) Stock Quote, History and News - Yahoo Finance
Nuvasive Inc (NUVA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!